Amgen (AMGN) Tax Provisions (2009 - 2026)

Amgen has reported Tax Provisions for 18 years, with the latest figure at $393.0 million in Q2 2026.

• On a quarterly basis, Tax Provisions rose 188.97% year-over-year to $393.0 million in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 91.8% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 143.74% from the prior year.
• Tax Provisions was $393.0 million for Q2 2026 at Amgen, up from $265.0 million in the prior quarter.
• The five-year high for Tax Provisions was $705.0 million in Q3 2025, with the low at $45.0 million in Q1 2024.
• Average Tax Provisions over 5 years is $243.0 million, with a median of $215.5 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions slumped 92.51% in 2024, then surged 440.0% in 2025.
• Over 5 years, Tax Provisions stood at $132.0 million in 2022, then tumbled by 35.61% to $85.0 million in 2023, then jumped by 82.35% to $155.0 million in 2024, then advanced by 16.77% to $181.0 million in 2025, then jumped by 117.13% to $393.0 million in 2026.
• The last three Tax Provisions figures came in at $393.0 million (Q2 2026), $265.0 million (Q1 2026), and $181.0 million (Q4 2025), per Business Quant data.